Hemispherx Biopharma (HEB) Reports Q1 Loss of $0.02/Share
Tweet
Share
E-mailGet Alerts HEB Hot Sheet
Price: $1.80 --0%
Financial Fact:
Research and development: 900K
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Research and development: 900K
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Hemispherx Biopharma (NYSE: HEB) reported Q1 EPS of ($0.02), versus ($0.02) reported last year.
Cash, cash equivalents and marketable securities were approximately $17,005,000 at March 31, 2015 as compared to $16,108,000 as of December 31, 2014.
For earnings history and earnings-related data on Hemispherx Biopharma (HEB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
